Explore All 44 Going Private Life Science Deals - Search the Database Free
M&A Deal Summary |
|
|---|---|
| Date | May 26, 2021 |
| Target | Kiadis Pharma |
| Sector | Life Science |
| Buyer(s) | Sanofi |
| Deal Type | Going Private |
FILTER BY
| Category | Company |
|---|---|
| Founded | 1994 |
| Sector | Life Science |
| Employees | 82,878 |
| Revenue | 44.3B EUR (2024) |
Sanofi is a French multinational pharmaceutical company. Sanofi was founded in 1994 and is based in Paris, France.
| Deal Context for Buyer | # |
|---|---|
| Overall | 24 of 32 |
| Sector: Life Science | 15 of 23 |
| Type: Going Private | 2 of 2 |
| Country: Netherlands | 1 of 1 |
| Year: 2021 | 2 of 4 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-01-11 |
Kymab
Cambridge, United Kingdom Kymab is a clinical-stage biopharmaceutical company developing fully human monoclonal antibody therapeutics with a focus on immune-mediated diseases and immuno-oncology using its proprietary, integrated platforms collectively called IntelliSelect®. Kymab’s IntelliSelect Transgenic platforms contain a full diversity of human antibodies, making them the most comprehensive antibody platforms available. Kymab was founded in 2010 and is based in Cambridge, United Kingdom. |
Buy | $1.5B |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-08-03 |
Translate Bio
Lexington, Massachusetts, United States Translate Bio is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, or to prevent infectious diseases by generating protective immunity. Translate Bio was founded in 2011 and is based in Lexington, Massachusetts. |
Buy | $3.2B |
